Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants

Fulcrum Therapeutics, Inc.

Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.
Gross proceeds of $175M; net proceeds estimated at $164.1M (or $188.1M if underwriter option exercised).
Offering upsized; underwriters granted 30-day option to purchase up to 1,944,456 additional shares.
Net proceeds to fund general corporate purposes, including R&D, clinical trials, and potential acquisitions.
Closing expected on or about December 11, 2025, subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.